Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy

被引:61
作者
Bizama, Carolina [1 ]
Garcia, Patricia [1 ]
Espinoza, Jaime A. [1 ]
Weber, Helga [2 ]
Leal, Pamela [2 ]
Nervi, Bruno [3 ]
Carlos Roa, Juan [1 ,4 ]
机构
[1] Pontificia Univ Catolica Chile, Sch Med, Ctr Investigat Translat Oncol, Dept Pathol, Santiago 8330024, Chile
[2] Univ La Frontera, Dept Pathol, Sch Med, CEGIN BIOREN, Temuco 4811230, Chile
[3] Pontificia Univ Catolica Chile, Sch Med, Dept Hematol Oncol, Santiago 26767000, Chile
[4] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDiS, Santiago 8330024, Chile
关键词
Gallbladder cancer; Genetic and epigenetic alterations; Intracellular pathways; Directing rational cancer therapy; BILIARY-TRACT CANCER; GROWTH-FACTOR-RECEPTOR; PHASE-II TRIAL; HEDGEHOG SIGNALING PATHWAY; GAMMA-SECRETASE INHIBITOR; HIGH-INCIDENCE AREAS; K-RAS; TUMOR-SUPPRESSOR; CELL-PROLIFERATION; ANOMALOUS JUNCTION;
D O I
10.1016/j.ctrv.2015.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gallbladder cancer is the most common and aggressive malignancy of the biliary tract. The complete surgical resection is the only potentially curative approach in early stage; however, most cases are diagnosed in advanced stages and the response to traditional chemotherapy and radiotherapy is extremely limited, with modest impact in overall survival. The recent progress in understanding the molecular alterations of gallbladder cancer has shown great promise for the development of more effective treatment strategies. This has mainly resulted from the identification of molecular alterations in relevant intracellular signaling pathways Hedgehog, PI3K/AKT/mTOR, Notch, ErbB, MAPK and angiogenesis which are potential tailored targets for gallbladder cancer patients. This review discusses the recent remarkable progress in understanding the molecular alterations that represent novel prognosis molecular markers and therapeutic targets for gallbladder cancer, which will provide opportunities for research and for developing innovative strategies that may enhance the benefit of conventional chemotherapy, or eventually modify the fatal natural history of this orphan disease. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:222 / 234
页数:13
相关论文
共 141 条
[1]   Intracholecystic Papillary-Tubular Neoplasms (ICPN) of the Gallbladder (Neoplastic Polyps, Adenomas, and Papillary Neoplasms That Are ≥ 1.0 cm) Clinicopathologic and Immunohistochemical Analysis of 123 Cases [J].
Adsay, Volkan ;
Jang, Kee-Taek ;
Carlos Roa, Juan ;
Dursun, Nevra ;
Ohike, Nobuyuki ;
Bagci, Pelin ;
Basturk, Olca ;
Bandyopadhyay, Sudeshna ;
Cheng, Jeanette D. ;
Sarmiento, Juan M. ;
Tapia Escalona, Oscar ;
Goodman, Michael ;
Kong, So Yeon ;
Terry, Paul .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (09) :1279-1301
[2]   MEK and the inhibitors: from bench to bedside [J].
Akinleye, Akintunde ;
Furqan, Muhammad ;
Mukhi, Nikhil ;
Ravella, Pavan ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[3]   The risk of gallbladder cancer from polyps in a large multiethnic series [J].
Aldouri, A. Q. ;
Malik, H. Z. ;
Waytt, J. ;
Khan, S. ;
Ranganathan, K. ;
Kummaraganti, S. ;
Hamilton, W. ;
Dexter, S. ;
Menon, K. ;
Lodge, J. P. ;
Prasad, K. R. ;
Toogood, G. J. .
EJSO, 2009, 35 (01) :48-51
[4]   Everolimus in colorectal cancer [J].
Altomare, Ivy ;
Hurwitz, Herbert .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (04) :505-513
[5]   Diagnosis and Management of Gallbladder Cancer [J].
Andren-Sandberg, Ake .
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2012, 4 (07) :293-299
[6]  
[Anonymous], CANC SCI
[7]  
[Anonymous], NCT01425879
[8]  
[Anonymous], MOL SURG PATHOLOGY
[9]  
[Anonymous], NAT GENET
[10]  
[Anonymous], APPL IMMUNOHISTOCHEM